We are live on ! Find out more
BCDA icon

BioCardia
BCDA

24 hedge funds and large institutions have $1.37M invested in BioCardia in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

13,600% more call options, than puts

Call options by funds: $137K | Put options by funds: $1K

700% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 1

92% more capital invested

Capital invested by funds: $710K → $1.37M (+$656K)

50% more funds holding

Funds holding: 16 → 24 (+8)

0.12% more ownership

Funds ownership: 0.51% → 0.63% (+0.12%)

Holders
24
Holders Change
+8
Holders Change %
+50%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
8
Reduced
1
Closed
–
Calls
$137K
Puts
$1K
Net Calls
+$136K
Net Calls Change
+$26K

Top Buyers

Rank Fund Capital Flow
1
CM
CM Management
Florida
+$54.1K
2
Renaissance Technologies
Renaissance Technologies
New York
+$42.1K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$35.4K
4
VF
Virtu Financial
New York
+$22.4K
5
Citadel Advisors
Citadel Advisors
Florida
+$18.2K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$292

BCDA Hedge Fund Activity: Q4 2023 in Review

24 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in BioCardia (BCDA) for Q4 2023, worth a combined $1.37M — up 92% from $710K a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new BCDA positions and 0 closed out — a net gain of 8 holders — while 8 added to existing stakes and 1 trimmed.

The largest buyer was CM Management, adding an estimated $54.1K. The largest seller was Morgan Stanley, cutting an estimated $292.

  • 24 institutional investors held BioCardia (BCDA) as of Q4 2023, up from 16 in Q3 2023.
  • Funds reported $1.37M of BioCardia stock for Q4 2023, up 92% quarter-over-quarter.
  • 8 funds opened new BioCardia positions in Q4 2023 and 0 closed out, a net change of +8 holders.
  • The largest BioCardia buyer in Q4 2023 was CM Management, an estimated $54.1K added.
  • The largest BioCardia seller in Q4 2023 was Morgan Stanley, an estimated $292 sold.

Based on aggregated 13F filings for Q4 2023.